These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22404399)

  • 1. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
    Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
    J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
    Fiocchi SC; Selting KA; Rosenberg MP; Kolli P; Lenaz G; Henry C
    J Vet Intern Med; 2011; 25(4):897-902. PubMed ID: 21736623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
    Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
    Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
    Silver M; Rusk A; Phillips B; Beck E; Jankowski M; Philibert J; Hahn K; Hershey E; McKeegan E; Bauch J; Krivoshik A; Khanna C
    J Vet Intern Med; 2012; 26(2):349-54. PubMed ID: 22369215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.
    Boulin M; Hillon P; Cercueil JP; Bonnetain F; Dabakuyo S; Minello A; Jouve JL; Lepage C; Bardou M; Wendremaire M; Guerard P; Denys A; Grandvuillemin A; Chauffert B; Bedenne L; Guiu B
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1301-13. PubMed ID: 24738629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia.
    Moore AS; Ruslander D; Cotter SM; Rand WM; L'Heureux DA
    J Am Vet Med Assoc; 1995 May; 206(10):1550-4. PubMed ID: 7775231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
    Lee MH; Kim SY
    Leuk Lymphoma; 2016 Oct; 57(10):2268-74. PubMed ID: 26750985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.
    Marconato L; Finotello R; Bonfanti U; Dacasto M; Beatrice L; Pizzoni S; Leone VF; Balestra G; Furlanello T; Rohrer Bley C; Aresu L
    J Vet Intern Med; 2015; 29(2):620-5. PubMed ID: 25818216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation of single-agent vinblastine in dogs.
    Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
    J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.
    Anota A; Boulin M; Dabakuyo-Yonli S; Hillon P; Cercueil JP; Minello A; Jouve JL; Paoletti X; Bedenne L; Guiu B; Bonnetain F
    BMJ Open; 2016 Jun; 6(6):e010696. PubMed ID: 27342239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
    Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
    J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
    Fukushima T; Yamashita T; Goto N; Ueda T; Okabe KI; Kuraishi Y; Ohno R; Urabe A; Ogawa M
    Int J Hematol; 2001 Oct; 74(3):297-302. PubMed ID: 11721966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer.
    Marconato L; Rohrer Bley C; Leone VF; Finotello R
    Vet Comp Oncol; 2020 Dec; 18(4):838-842. PubMed ID: 32510792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for three days without concurrent furosemide as part of a chemotherapeutic treatment for lymphoma: 57 cases (2007-2012).
    Best MP; Fry DR
    J Am Vet Med Assoc; 2013 Oct; 243(7):1025-9. PubMed ID: 24050570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.